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Complete revascularization” traditionally has been defined as
lleviating all angiographically apparent coronary artery steno-
es. For many years the dogma in interventional cardiology has
een to achieve complete revascularization when performing
ercutaneous coronary intervention (PCI). The impetus be-
ind this teaching stems from early reports demonstrating
mproved outcomes after achieving complete revascularization
ith coronary artery bypass grafting (1). Improvements in
nterventional equipment and technique and, in particular, the
dvent of drug-eluting stents have all made it more attractive
nd easier to achieve complete revascularization with PCI,
urther solidifying it as one of our primary goals. This has
ccurred despite early reports suggesting that complete ana-
omic revascularization was important only when there was a
arge ischemic burden (2,3).
See page 180
The importance of ischemia in predicting adverse cardiac
utcomes has been known for some time (4). Relief of
schemia results in improved outcomes, whereas PCI of
on–ischemia-producing lesions provides no additional
enefit over medical therapy and might actually increase
dverse events (5,6). Recent data are now leading to a
aradigm shift away from our obsession with complete
natomic revascularization toward the realization that
quivalent if not improved outcomes can be achieved with a
unctionally complete revascularization (i.e., stenting of
schemia-producing lesions and medical treatment of non–
schemia-producing ones). For example, the FAME (Frac-
ional Flow Reserve versus Angiography for Multivessel
valuation) Study showed that fractional flow reserve
FFR)-guided PCI results in fewer stents being placed, yet
utcomes are significantly improved (7). At 1 year, the rate
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.p
From the Division of Cardiovascular Medicine, Stanford University Medical
enter, Stanford, California.f major adverse cardiac events was significantly reduced,
nd each individual component (death, myocardial infarc-
ion and the need for repeat revascularization) was reduced
y 30% to 40% in patients randomized to FFR-guided PCI
f their multivessel coronary disease, compared with those
andomized to standard angiographic guidance.
Measuring FFR allows the interventionalist to identify
tenoses that are responsible for ischemia and are likely to
enefit most from PCI. Likewise, it identifies lesions that
ight appear significant angiographically but are not causing
schemia and therefore can be safely treated medically. In this
ay, the benefits of PCI are maximized, and its risks are
inimized. In the FAME study, the patients randomized to
ngiography guidance had PCI performed on a significantly
reater number of lesions, resulting in greater stent number
nd length. This difference not only exposed patients in this
rm to greater risk at the time of the procedure but also to
reater risk for restenosis and stent thrombosis manifesting as
higher rate of death, myocardial infarction, and the need for
epeat revascularization at 1 year.
This potential downside to indiscriminate stenting is also
ighlighted in the current report by Shirai et al. (8) in this issue
f JACC: Cardiovascular Interventions. In this evaluation of over
0,000 patients treated with sirolimus-eluting stents as part of
he j-Cypher registry, the investigators found a significant
orrelation between stent length and the rates of target lesion
evascularization, thrombosis, and death or myocardial infarc-
ion at 3-year follow-up. After adjusting for differences in
aseline characteristics, the quartile of patients with the great-
st total stent length continued to have increased rates of target
esion revascularization and thrombosis, although the rate of
eath and myocardial infarction was no longer significantly
ifferent. Interestingly, total stent length/lesion (as opposed to
otal stent length/patient) correlated only with increased target
esion revascularization and not with thrombosis, suggesting
hat deploying a slightly longer stent to make sure one covers
he entire lesion is not as hazardous as placing another stent in
second lesion. This is different from other studies, which have
ound increasing rates of stent thrombosis with each additional
illimeter of stent length, and it might be because stent
hrombosis rates were very low in the present study in all
roups, when evaluated on a per-lesion basis (9).
The strengths of this study include its size, the fact that
atients were consecutively enrolled from a number of Japanese
enters, and the relatively long-term follow-up. Some weak-
esses include that, although patients were consecutively en-
olled, a large number were excluded from this analysis because
hey were treated with bare-metal stents, other drug-eluting
tents, or angioplasty in conjunction with a sirolimus-eluting
tent. The study included only Japanese patients, and there was
large variability in the number of patients included from each
f the participating centers, both of which might limit the
pplicability of these findings. We are never told the number of
atients lost to follow-up in each group. Another main
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190imitation of this study is inherent in its design as a registry;
here were significant differences in baseline patient and lesion
haracteristics in those who had the greatest stent length,
hich might have contributed to the increased rate of adverse
utcomes in this group, despite attempts to adjust for these
ariables. Finally, there seems to be an inflection point in the
ates of target lesion revascularization at 6 months depicted in
igure 2A of Shirai et al. (8), which might be due to routine
ngiographic follow-up and which might exaggerate the dif-
erences in target lesion revascularization rates between the
ifferent stent lengths.
Another aspect of this study worth discussing is the rate of
tent thrombosis reported in this cohort. It is not clear why the
uthors only reported rates of definite stent thrombosis, instead
f including probable and possible stent thrombosis like they
ad in previous reports from this registry (10). At 3 years, the
ate of definite stent thrombosis was approximately 1%. This is
imilar or somewhat lower than rates reported in other regis-
ries, and as the authors mention, it is significantly lower than
he rate seen in the SYNTAX (Synergy between Percutaneous
oronary Intervention with Taxus and Cardiac Surgery) study.
he differences in rates of stent thrombosis might be explained
ot only by ethnic differences, as hypothesized by the authors,
ut also by use of different drug-eluting stents, differing
efinitions of stent thrombosis, and procedural differences
e.g., more routine use of intravascular ultrasound) in the
urrent study (11–14). It is impressive that, even with this low
verall rate of stent thrombosis, significant differences were
een in the rate of stent thrombosis, depending on the length
f stent deployed.
The authors should be congratulated for compiling long-
erm follow-up in such a large number of patients after PCI
ith sirolimus-eluting stents. Their report adds to the pub-
ished data demonstrating that event rates increase significantly
ith increasing stent length. As they suggest, a more judicious
pproach to PCI with the aim of achieving functionally
omplete revascularization and not necessarily complete ana-
omic revascularization could result in improved outcomes.
learly, in some patients multiple and long stents are neces-
ary, but this decision should be guided by relieving ischemia
nd not by the coronary angiogram alone. In other words, in
he case of drug-eluting stent length, less is more . . . more or
ess.
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